SEARCH:   Advanced

Blood, 15 September 2004, Vol. 104, No. 6, pp. 1784-1792. Prepublished online as a Blood First Edition Paper on June 8, 2004; DOI 10.1182/blood-2004-01-0251. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-01-0251v1 104/6/1784    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Trkola, A. Articles by Günthard, H. F. Search for Related Content PubMed PubMed Citation Articles by Trkola, A. Articles by Günthard, H. F. Related Collections Immunobiology Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  IMMUNOBIOLOGY Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point Alexandra Trkola, Herbert Kuster, Christine Leemann, Annette Oxenius, Catherine Fagard, Hansjakob Furrer, Manuel Battegay, Pietro Vernazza, Enos Bernasconi, Rainer Weber, Bernard Hirschel, Sebastian Bonhoeffer, and Huldrych F. Günthard, for the Swiss HIV Cohort Study From the Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Switzerland; Institute for Microbiology and Institute for Ecology, Eidgenossische Technische Hochschule (ETH) Zentrum Zurich, Switzerland; Division of Infectious Diseases, University Hospital Geneva, Switzerland; Division of Infectious Diseases, Inselspital, Bern, Switzerland; Division of Infectious Diseases, University Hospital Basel, Switzerland; Medizinische Klinik, University Hospital St Gallen, Switzerland; and Division of Infectious Diseases, Ospedale Civico, Lugano, Switzerland. We analyzed the humoral immune response in 46 patients following structured treatment interruption (STI) to investigate the general potential of therapeutic vaccination in chronic HIV-1 infection. Evoked antibody titer increases to glycoprotein 120 (gp120) and p24 were low during 4 short-term STIs and only reached significance during a fifth long-term interruption. Although induction of binding antibodies to viral antigens was not associated with potent suppression of viremia, we observed that individuals with a rapid and high response to p24, and to a lesser extent also to gp120, lowered their viral set points significantly. Of note, the increase of the anti-p24 response correlated with specific CD4 T helper frequency to this antigen. Despite induction of binding antibody responses, which correlated with improved viral control, the increase in neutralizing activity was marginal and did not lead to this enhanced viral suppression. However, a subgroup of patients who potently suppressed viremia independently of STI had significantly higher pre-existing neutralization titers, suggesting a role of humoral immunity in conferring potent protection. In summary, measuring the kinetics of antibody responses provided a marker to validate the responsiveness and capacities of the immune system of HIV-1-infected individuals and reflected the patients' ability to decrease viral set points. (Blood. 2004;104:1784-1792) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. Huber, V. von Wyl, C. G. Ammann, H. Kuster, G. Stiegler, H. Katinger, R. Weber, M. Fischer, H. Stoiber, H. F. Gunthard, et al. Potent Human Immunodeficiency Virus-Neutralizing and Complement Lysis Activities of Antibodies Are Not Obligatorily Linked J. Virol., April 15, 2008; 82(8): 3834 - 3842. [Abstract] [Full Text] [PDF] S. Gorantla, H. Sneller, L. Walters, J. G. Sharp, S. J. Pirruccello, J. T. West, C. Wood, S. Dewhurst, H. E. Gendelman, and L. Poluektova Human Immunodeficiency Virus Type 1 Pathobiology Studied in Humanized BALB/c-Rag2-/-{gamma}c-/- Mice J. Virol., March 15, 2007; 81(6): 2700 - 2712. [Abstract] [Full Text] [PDF] J. M. Marcelino, H. Barroso, F. Goncalves, S. M. Silva, C. Novo, P. Gomes, R. Camacho, and N. Taveira Use of a New Dual-Antigen Enzyme-Linked Immunosorbent Assay To Detect and Characterize the Human Antibody Response to the Human Immunodeficiency Virus Type 2 Envelope gp125 and gp36 Glycoproteins J. Clin. Microbiol., February 1, 2006; 44(2): 607 - 611. [Abstract] [Full Text] [PDF] K. J. Metzner, W. J. Moretto, S. M. Donahoe, X. Jin, A. Gettie, D. C. Montefiori, P. A. Marx, J. M. Binley, D. F. Nixon, and R. I. Connor Evaluation of CD8+ T-cell and antibody responses following transient increased viraemia in rhesus macaques infected with live, attenuated simian immunodeficiency virus J. Gen. Virol., December 1, 2005; 86(12): 3375 - 3384. [Abstract] [Full Text] [PDF] A. P Galvani The role of mutation accumulation in HIV progression Proc R Soc B, September 7, 2005; 272(1574): 1851 - 1858. [Abstract] [Full Text] [PDF] B. Joos, A. Trkola, M. Fischer, H. Kuster, P. Rusert, C. Leemann, J. Boni, A. Oxenius, D. A. Price, R. E. Phillips, et al. Low Human Immunodeficiency Virus Envelope Diversity Correlates with Low In Vitro Replication Capacity and Predicts Spontaneous Control of Plasma Viremia after Treatment Interruptions J. Virol., July 15, 2005; 79(14): 9026 - 9037. [Abstract] [Full Text] [PDF] P. Rusert, H. Kuster, B. Joos, B. Misselwitz, C. Gujer, C. Leemann, M. Fischer, G. Stiegler, H. Katinger, W. C. Olson, et al. Virus Isolates during Acute and Chronic Human Immunodeficiency Virus Type 1 Infection Show Distinct Patterns of Sensitivity to Entry Inhibitors J. Virol., July 1, 2005; 79(13): 8454 - 8469. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020